Recently approved treatments for r/r HL and NHL subtypes include anti-CD30 antibody-drug conjugate brentuximab vedotin, PD1 inhibitors (pembrolizumab and nivolumab), Bruton’s tyrosine kinase inhibitors (ibrutinib and acalabrutinib), phosphoinositide 3-kinase γ and/or δ inhibitors (idelalisib, copanlisib and duvelisib) and CD19 chimeric antigen receptor (CAR) T cell therapy (tisagenlecleucel and axicabtagene ciloleucel) (Table 1) (1, 2, 29). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.